Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920514 | 0.84 | PKM (0.35) | HSP90AB1PKMSMN1; SMN2KDM4EPOLB | |
| SCHEMBL1935371 | 0.84 | KMT2A (0.36) | HSP90AB1PKMSMN1; SMN2KDM4EPOLB | |
| SCHEMBL30718870 | 0.84 | HSP90AB1 (0.43) | HSP90AB1PKMABCB1SMN1; SMN2KDM4E | |
| SCHEMBL17119856 | 0.79 | LMNA (0.33) | HSP90AB1PKMLMNAL3MBTL1 | |
| SCHEMBL3029389 | 0.76 | TLR8 (0.41) | PKMKDM4EMAPTLMNAL3MBTL1 | |
| SCHEMBL1898608 | 0.76 | MAPK1 (0.34) | PKMSMN1; SMN2KDM4ELMNAL3MBTL1 | |
| SCHEMBL15147055 | 0.74 | SMN1; SMN2 (0.33) | PKMSMN1; SMN2MAPTLMNAL3MBTL1 | |
| SCHEMBL26977406 | 0.72 | HSP90AB1 (0.41) | HSP90AB1PKMABCB1 | |
| SCHEMBL7537282 | 0.71 | HSP90AB1 (0.48) | HSP90AB1PKMABCB1SMN1; SMN2KDM4E | |
| SCHEMBL721780 | 0.70 | KMT2A (0.36) | HSP90AB1SMN1; SMN2KDM4EPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140242027-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242027-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2014-08-28 | — | — | US | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | PIK3CA, CDKN1A, PIK3CD | HSP90AB1 3879/4885PKM 637/4885ABCB1 931/4885 |
| US-20140242027-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | PNP, XDH, PNPO | HSP90AB1 4678/4885PKM 874/4885ABCB1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.